Addressing Patient Questions on Ketamine, Psychedelic Medicine Treatments for Mental Health

Pharmacy Times interviewed Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, on the implications of a survey that showed 65% of affected Americans want access to psychedelics for the treatment of mental health conditions.

Specifically, data have shown that patients with treatment-resistant anxiety, depression, and post-traumatic stress disorder are among those who would benefit from an expanded therapeutic regimen that includes psychedelic medicines, which have been found to be both effective and safe in the treatment of these conditions.

During the discussion, Marques addressed what questions patients may ask their trusted health care professionals, such as their pharmacists, about ketamine and other psychedelic treatments.